Ophthalmology Patient Support Materials

The SmartSight programme provides inspirational, engaging and educational resources for patients with macular conditions and their loved ones. All materials have been designed by Bayer with the support of the leading eye care charities.

To order any physical copies of the materials below and to find out about our support materials for healthcare professionals, please contact the Bayer medical information department on

EYLEA® (aflibercept) 8 mg Patient Booklet

This Bayer-funded patient booklet provides essential information for patients receiving EYLEA 8 mg for wAMD, DMO or RVO. It covers treatment expectations, potential side effects, and includes tools like an Amsler grid for vision monitoring. The booklet also offers access to educational videos and additional resources to support patients throughout their treatment.

SMARTSTART Guides to wAMD, DMO and RVO

Booklets for patients with macular conditions who have been prescribed anti-VEGF therapy. These booklets provide information about the patients' condition and treatment journey. SmartStart guides are recertified for use with original date of preparation.

SmartSight Patient Safety Booklet

A booklet to help people with impaired vision stay safe and look after themselves at home and when out and about. It provides useful tips and ideas of changes to make to help them cope with macular degeneration. Your guide to safe living booklet is recertified for use with original date of preparation.

EYLEA Patient Guides

All patient guides are recertified for use with original date of preparation.

Additional Online Resources from Bayer

Discover SmartBrowse for resources that may support everyday living with visual impairment and explore the Visual Acuity Tool to experience how macular disease can alter vision. These websites are informational only and not a substitute for seeking medical advice.

BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion. DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. ROP, retinopathy of prematurity. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor. wAMD, wet age-related macular degeneration.

Prescribing information for EYLEA® (aflibercept)

PP-EYL-GB-3152 | May 2026